El interés en corto de VanEck Merk Gold ETF da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de VanEck Merk Gold ETF. Los datos de interés en corto se actualizan cada dos semanas.

VanEck Merk Gold ETF (ARCA:OUNZ), Informe de interés en corto

The investment seeks to provide investors with an opportunity to invest in gold through the shares and be able to take delivery of physical gold in exchange for those shares.

VanEck Merk Gold Trust

VanEck Merk Gold ETF

Small Cap Consumer Research analyst Eric Beder reiterates Vince Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) with a Buy and maintains $6 price target.

News

Price Target

Reiteration

Analyst Ratings

VNCE

Small Cap Consumer Research Reiterates Buy on Vince Holding, Maintains $6 Price Target

Data corroborate previously reported preclinical data demonstrating certepetide's ability to enhance the effectiveness of immunotherapy
Preliminary results to be presented at the 2025 ASCO Gastrointestinal Cancers Symposium
BASKING RIDGE, N.J. and SUBIACO, Australia, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTA#NASDAQ">LSTA</a>) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, and WARPNINE Incorporated ("WARPNINE"), Western Australia's first not-for-profit clinical research organization for pancreatic, gastro-intestinal and rare cancers, today announced encouraging preliminary results from the Phase 1b/2a iLSTA trial (<a href="https://www.globenewswire.com/Tracker?data=viG6Z8rb5yakmCziK5MC4KHIHD449o_0_iwBwzOnKLuIVX9ogOPIlIPp1gF8kKV4bkOsW4cHmYy5OZllI3q1fdfHwQ_EiqAKt0OJn1dwseNnLMKSutHtNTo4FzoF1DPTxQwyJFbH0lXRFKDo7QySmQ==">ACTRN12623000223639</a>) evaluating certepetide (formerly LSTA1), Lisata's proprietary investigational iRGD cyclic peptide product candidate, in combination with standard-of-care (SoC) chemotherapy and immunotherapy as a first-line treatment in locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC). The preliminary data will be presented in a poster session, entitled, "Immunotherapy combined with a novel iRGD peptide plus nab-paclitaxel and gemcitabine for locally advanced pancreatic ductal adenocarcinoma: A prospective study," at the 2025 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium on Friday, January 24, 2025 at 11:30 a.m. - 1:00 p.m. (PST) in San Franscisco, California. For a detailed summary of the poster presentation, please see the abstract available on the ASCO GI website: <a href="https://www.globenewswire.com/Tracker?data=xhbTLxEjS_qv4xxw0rdbf9Rt0I_ukgclLSLtzTm27CY4aH8IsYbd4usSpVvBiLpC4lPd65aFQ8ovirYYzJtCon_gypsrzb3eZ8Am3EwukOPCVshYZxApc7bUzgoQWUApN9BvOUHo20-Tx0AxvGFbFPmy04pHaRoIuiyMBuEeQkZuPCIJxEmyVsPtYCxVjX4u">https://meetings.asco.org/abstracts-presentations/241611</a>
The Phase 1b/2a randomized, single-blind, single-center, safety and pharmacodynamic iLSTA trial, being conducted at St John of God Subiaco Hospital in Western Australia, a leading center for clinical research and innovation, is evaluating certepetide in combination with SoC chemotherapy (nab-paclitaxel and gemcitabine) plus SoC immunotherapy (durvalumab) versus SoC alone in patients with locally advanced non-resectable PDAC. This collaboration highlights the strength of combining global expertise with local excellence to address the urgent needs of patients with pancreatic cancer. Participants in the iLSTA trial were divided into three treatment cohorts (1:1:4 ratio): Cohort 1 (n=5) received SoC chemotherapy in combination with placebo durvalumab and placebo certepetide. Cohort 2 (n=5) received SoC chemotherapy plus certepetide and placebo durvalumab. Cohort 3 (n=20) received SoC chemotherapy plus durvalumab and certepetide. The preliminary results, representing an interim analysis of the first 17 of 30 targeted patients of the iLSTA trial are as follows:
Five of 16 patients evaluable by RECIST criteria experienced a partial response after 2 cycles of treatment (4 patients were in cohort 3), with the remaining 11 patients presenting with stable disease. After 4 cycles of treatment, 9 of 16 patients demonstrated partial response (8 patients were in cohort 3). Of the remaining 7 patients, 6 demonstrated stable disease, and 1 patient (cohort 2) exhibited a complete response. Fourteen of 17 patients who completed 4 treatment cycles showed a decrease in CA19-9 levels. Six patients demonstrated &gt;90% reduction in CA19-9 (5 of whom in cohort 3), with the remaining 8 patients showing a &gt;50% reduction in CA19-9 levels (6 of whom in cohort 3). Five patients had their repeat biopsies analyzed for tumor infiltrating lymphocytes (4 of whom from cohort 3), with all patients showing significant immune cell infiltration (15% to 50% stroma infiltration). These results demonstrate the potential value of adding certepetide to the SoC regimen consisting of gemcitabine, nab-paclitaxel, and durvalumab in this patient population.

Biotech

General

LSTA

Lisata And WARPNINE Announces Interim Phase 1b/2a Results For Certepetide In Pancreatic Cancer; 56% Show Partial Response After 4 Cycles, With Up To 90% Reduction In CA19-9 Levels; Results To Be Presented At 2025 ASCO GI Symposium

Barclays analyst Jared Shaw maintains Wintrust Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTFC#NASDAQ">WTFC</a>) with a Overweight and raises the price target from $151 to $155.

WTFC

Barclays Maintains Overweight on Wintrust Finl, Raises Price Target to $155

Carter Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARE#NASDAQ">CARE</a>) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.24 by 54.17 percent. This is a 1950 percent increase over losses of $(0.02) per share from the same period last year.

Earnings

CARE

Carter Bankshares Q4 Adj $0.37 Beats $0.24 Estimate

WIIM

BANC

Bank of California shares are trading higher after the company reported better-than-expected Q4 EPS results.

ATXS

Astria Therapeutics Initiates Phase 1a Trial Of STAR-0310 For Treatment Of Atopic Dermatitis

Cass Information Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASS#NASDAQ">CASS</a>) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.21 by 57.14 percent. This is a 45.9 percent decrease over earnings of $0.61 per share from the same period last year. The company reported quarterly sales of $50.37 million which beat the analyst consensus estimate of $49.48 million by 1.80 percent. This is a 0.72 percent decrease over sales of $50.74 million the same period last year.

CASS

Cass Information Sys Q4 EPS $0.33 Beats $0.21 Estimate, Sales $50.37M Beat $49.48M Estimate

Heritage Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HFWA#NASDAQ">HFWA</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.45 by 13.33 percent. This is a 15.91 percent increase over earnings of $0.44 per share from the same period last year. The company reported quarterly sales of $57.053 million which missed the analyst consensus estimate of $60.685 million by 5.98 percent. This is a 12.48 percent increase over sales of $50.724 million the same period last year.

Earnings Beats

Earnings Misses

HFWA

Heritage Financial Q4 2024 Adj. EPS $0.51 Beats $0.45 Estimate, Sales $57.053M Miss $60.685M Estimate

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">143.00</td>
<td align="right">0.82</td>
<td align="right">0.57</td>
<td>7.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">140.99</td>
<td align="right">0.74</td>
<td align="right">0.52</td>
<td>22.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">78.45</td>
<td align="right">0.13</td>
<td align="right">0.16</td>
<td>402</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">50.49</td>
<td align="right">0.08</td>
<td align="right">0.15</td>
<td>56.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">41.11</td>
<td align="right">0.01</td>
<td align="right">0.02</td>
<td>478</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">239.73</td>
<td align="right">-1.66</td>
<td align="right">-0.69</td>
<td>12.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">98.71</td>
<td align="right">-0.54</td>
<td align="right">-0.55</td>
<td>1.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">229.38</td>
<td align="right">-0.65</td>
<td align="right">-0.29</td>
<td>415</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">77.18</td>
<td align="right">-0.04</td>
<td align="right">-0.06</td>
<td>1.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">88.72</td>
<td align="right">-0.02</td>
<td align="right">-0.03</td>
<td>653</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alert provides traders with a compiled way to read macro-level market trends. Investors garner a particular interest in sector movers to better determine sectors that are over- or under-performing to make better investing decisions on exchange-traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For January 23, 2025

Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) reported quarterly adjusted earnings of $0.31 per share which beat the analyst consensus estimate of $0.22 by 40.91 percent. This is a 14.81 percent increase over earnings of $0.27 per share from the same period last year. The company reported quarterly sales of $5.72 billion which missed the analyst consensus estimate of $5.99 billion by 4.51 percent. This is a 3.13 percent decrease over sales of $5.91 billion the same period last year.

Freeport-McMoRan Q4 Adj $0.31 Beats $0.22 Estimate, Sales $5.72B Miss $5.99B Estimate

Barclays analyst Alex Scott maintains Prudential Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRU#NYSE">PRU</a>) with a Equal-Weight and raises the price target from $127 to $128.

Barclays Maintains Equal-Weight on Prudential Financial, Raises Price Target to $128

LiveOne Surpasses 600,000 Tesla Users, Says 275,000 Are Ad-Supported Users

Barclays analyst Lauren Lieberman maintains Procter &amp; Gamble (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>) with a Equal-Weight and raises the price target from $155 to $159.

Barclays Maintains Equal-Weight on Procter & Gamble, Raises Price Target to $159

NOVAGOLD RESOURCES INC. ("NOVAGOLD" or "the Company") ((NYSE American, TSX:<a href="https://www.benzinga.com/stock/NG#TSX">NG</a>) today filed its 2024 fiscal year-end report and provided an update on its Tier One1 gold development project, Donlin Gold, which NOVAGOLD owns equally with Barrick Gold Corporation ("Barrick").
Details of the financial results for the year ended November 30, 2024, are presented in the consolidated financial statements and annual report on Form 10-K filed on January 23, 2025 which is available on the Company's website at <a href="http://www.novagold.com/">www.novagold.com</a>, on SEDAR+ at <a href="http://www.sedarplus.ca/">www.sedarplus.ca</a>, and on EDGAR at <a href="http://www.sec.gov/">www.sec.gov</a>. All amounts are in U.S. dollars unless otherwise stated.
As detailed in the above filings, NOVAGOLD held a strong treasury of approximately $101 million in cash and term deposits as of November 30, 2024, and reported net annual cash expenditures of $24.5 million — including $12.4 million to fund NOVAGOLD's share of the Donlin Gold project and $17.7 million in corporate general and administrative costs, below its 2024 expenditure guidance of $31.2 million. As NOVAGOLD is a development-stage company with no production, the Company reported earnings of ($45.6) million and earnings per share of ($0.14) for the 2024 fiscal year, reflecting expenditures in line with budget.

Guidance

NOVAGOLD Announces $101M Treasury As Of Nov 2024; Reports $24.5M Cash Expenditures; ($0.14) EPS For 2024 Fiscal Year

Electronic Arts Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) reported preliminary financial results for the third quarter on Wednesday.
EA said it previously anticipated mid-single-digit growth in live services net bookings, but now projects a mid-single-digit decline largely due to a slowdown in Global Football.
The Global Football franchise experienced a slowdown in the quarter as early momentum faded, the company said. Separately, Dragon Age only engaged approximately 1.5 million players during the quarter, about 50% lower than the company's expectations.
"During Q3, we continued to deliver high-quality games and experiences across our portfolio; however, Dragon Age and EA SPORTS FC 25 underperformed our net bookings expectations," said Andrew Wilson, CEO of EA.
EA shares fell 0.7% to close at $142.35 on Wednesday.
These analysts made changes to their price targets on EA following earnings announcement.
<ul>
<li>BMO Capital analyst Brian Pitz downgraded Electronic Arts from Outperform to Market Perform and lowered the price target from $160 to $145.</li>
<li>B of A Securities analyst Omar Dessouky downgraded Electronic Arts from Buy to Neutral and lowered the price target from $170 to $130.</li>
<li>Raymond James analyst Andrew Marok downgraded the rating for Electronic Arts from Outperform to Market Perform.</li>
</ul>
Considering buying EA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="599" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23080717/image-173-1024x599.png" alt="" class="wp-image-746743" style="width:525px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23080717/image-173-1024x599.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23080717/image-173-300x175.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23080717/image-173-768x449.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/23080717/image-173.png 1106w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43126364/jim-cramer-this-tech-stock-is-a-buy-amd-is-a-great-company">Jim Cramer: AMD Is A &#8216;Great&#8217; Company, Hold Onto Dow Inc.</a></li>
</ul>

Markets

These Analysts Cut Their Forecasts On Electronic Arts After Preliminary Q3 Results

Barclays analyst David Anderson maintains Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) with a Equal-Weight and lowers the price target from $32 to $30.

Barclays Maintains Equal-Weight on Halliburton, Lowers Price Target to $30

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

UPXI

Upexi Establishes Digital Currency Holding Company; Board Agrees To Make Investment In Portfolio Of Crypto Including Bitcoin

First Mid Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FMBH#NASDAQ">FMBH</a>) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $0.82 by 6.1 percent. This is a 7.45 percent decrease over earnings of $0.94 per share from the same period last year. The company reported quarterly sales of $58.95 million which met the analyst consensus estimate. This is a 2.59 percent increase over sales of $57.46 million the same period last year.

FMBH

First Mid Bancshares Q4 Adj $0.87 Beats $0.82 Estimate, Sales $58.95M Inline

GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>)&nbsp;shares are trading higher premarket on Thursday after it reported&nbsp;fourth-quarter&nbsp;adjusted revenue growth of&nbsp;16%&nbsp;year-over-year to&nbsp;$9.879 billion&nbsp;and GAAP revenue of&nbsp;$10.812 <a target="_blank" href="https://www.geaerospace.com/sites/default/files/geaerospace_webcast_pressrelease_01232025.pdf" rel="noreferrer noopener">billion</a>. The analyst consensus was&nbsp;$9.604 billion.
Commercial Engines &amp; Services&nbsp;revenue was $7.650 billion&nbsp;(+19%&nbsp;Y/Y) and Defense &amp; Propulsion Technologies&nbsp;revenue totaled $2.523 billion&nbsp;(+4%&nbsp;Y/Y).
Total orders increased&nbsp;46%&nbsp;Y/Y to&nbsp;$15.5 billion, with Commercial Engines &amp; Services&nbsp;+50% Y/Y&nbsp;and Defense &amp; Propulsion Technologies&nbsp;+22% Y/Y.
GE Aerospace&#8217;s adjusted operating profit margin expanded 450 bps to&nbsp;20.1%, with an adjusted operating profit of&nbsp;$1.988 billion, up&nbsp;49%&nbsp;in the quarter.
Adjusted EPS for the quarter was&nbsp;$1.32 (+103%&nbsp;Y/Y), <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beating the consensus of&nbsp;$1.04</a>.
GE Aerospace&#8217;s cash from operating activities for the fiscal year stood at&nbsp;$5.8 billion&nbsp;(+26%), while adjusted free cash flow rose&nbsp;28%.
The company repurchased shares worth more than $6 billion in 2024. Also, it disclosed share repurchase plans of $7 billion in 2025, while raising the dividend by 30%, subject to Board approval.
2025 Guidance: GE Aerospace&nbsp;expects adjusted revenue growth in the low double digits and adjusted EPS of&nbsp;$5.10 &#8211; 5.45<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener"> vs. the&nbsp;$5.22&nbsp;consensus</a>.
The company expects adjusted operating profit of&nbsp;$7.8 billion&nbsp;–&nbsp;$8.2 billion&nbsp;and adjusted Free Cash Flow of&nbsp;$6.3 billion&nbsp;–&nbsp;$6.8 billion.
GE Aerospace Chairman and CEO H. Lawrence Culp, Jr. said, &#8220;Looking to 2025, we expect double-digit revenue and EPS growth with greater than 100% free cash flow conversion. Guided by FLIGHT DECK, our proprietary lean operating model, I&#8217;m confident in our ability to accelerate output and deliver for our customers.&#8221;
Investors can gain exposure to the stock via&nbsp;TCW Transform Systems ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NETZ#NYSE">NETZ</a>)and&nbsp;iShares U.S. Aerospace &amp; Defense ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ITA#BATS">ITA</a>).
Price Action: GE shares are up 8.04% at $203.51 premarket at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/43152748/sp-500-hits-new-record-fear-among-us-investors-eases-but-fear-greed-index-remains-in-fear-zone" target="_blank" rel="noreferrer noopener">S&amp;P 500 Hits New Record As Netflix Reports Strong Results: Investor Sentiment Improves But Greed Index Remains In &#8216;Fear&#8217; Zone</a></li>
</ul>

Equities

Large Cap

Dividends

Buybacks

NETZ

GE Aerospace Q4 Earnings: EPS Beat, Dividend And Stock Buyback Hike, Strong FY25 Outlook And More

Barclays analyst Julian Mitchell maintains GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Overweight and raises the price target from $420 to $487.

Comments

VanEck Merk Gold ETF

Interés en corto

VanEck Merk Gold ETF (ARCA:OUNZ), Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL